BT-409 / Brenig Therap - LARVOL DELTA

BT-409: Brain-Selective NLRP3 Inhibitor Advancing to First-in-Human Evaluation (PRNewswire) - "The company has initiated a Phase 1 single ascending dose (SAD)/multiple ascending dose (MAD) study, with first dosing anticipated in early Q1 2026. The study is designed to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of BT-409 in healthy volunteers...Subject to successful completion of Phase 1, Brenig plans to advance BT-409 into proof-of-concept studies in Multiple Sclerosis and Parkinson's disease, evaluating the therapeutic potential of central inflammasome inhibition in neuroinflammation and neurodegeneration, including potential interactions with pathways involved in lysosomal and neuronal homeostasis."

First-in-human • New trial • Trial status • CNS Disorders • Multiple Sclerosis • Parkinson's Disease